Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib with Chemoradiation in EGFR-Mutant NSCLC (ASCENT)
NCT01553942Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2012
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Apr 2012; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01553942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553942.